NCT04703322 - A Study of Pexidartinib in Tenosynovial Giant Cell Tumor in Japan | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 15, 2021

Primary Completion Date

March 20, 2023

Study Completion Date

May 31, 2026

Conditions

Tenosynovial Giant Cell Tumor

Interventions

DRUG

Pexidartinib

400 mg twice daily for a total daily dose of 800 mg (each capsule contains 200 mg of pexidartinib for oral administration)

Trial Locations (6)

Nagoya University Hospital, Aichi

Kyushu University Hospital, Fukuoka

Kanazawa University Hospital, Ishikawa

National Hospital Organization Osaka National Hospital, Osaka

Osaka International Cancer Institute, Osaka

National Cancer Center Hospital, Tokyo